Oral bacteria may signal metabolic health and even contribute to obesity
Distinct oral microbiome signatures in obesity show altered sugar fermentation, increased lactate production, and inflammatory pathways, correlating with triglycerides and metabolic markers, suggesting saliva-based microbial profiling may serve as a noninvasive biomarker of cardiometabolic health.
February 14, 2026 / oral microbiome obesity / salivary metabolic biomarkers / lactate production insulin resistance / cardiometabolic risk indicators / microbiome metabolic health
Nourishing fat, nurturing health: The science of functional adipose tissue
February 13, 2025 / functional adipose tissue / adiponectin signaling / white adipose metabolism / obesity metabolic regulation / fatty liver disease prevention
Research highlights white adipose tissue as an essential endocrine organ regulating cholesterol and energy balance, with adiponectin signaling as a therapeutic target; AI-driven screening and dietary interventions aim to enhance metabolic health and address obesity-related disorders, including fatty liver disease.
Intermittent fasting does not seem to work for overweight or obese adults
February 16, 2026 / intermittent fasting obesity / weight loss clinical trials / Cochrane review fasting / obesity management evidence / time-restricted feeding outcomes
A Cochrane review of 22 randomized trials found intermittent fasting does not produce clinically meaningful weight loss in overweight or obese adults compared with standard dietary advice, highlighting limited long-term evidence for sustained obesity management.
AI-Designed Obesity Drug Delivers Over 31% Weight Loss in Preclinical Tests
February 13, 2026 / AI-designed obesity drug / GIP receptor antagonist / preclinical weight loss / next-generation obesity therapy / cardiometabolic drug development
An AI-designed, orally bioavailable GIP receptor antagonist demonstrated over 31% weight loss in preclinical models, targeting complementary metabolic pathways beyond GLP-1 to address obesity, type 2 diabetes, and cardiometabolic complications.
Canine obesity and its link to eye pressure
February 13, 2026 / canine obesity / intraocular pressure dogs / glaucoma risk factors / veterinary metabolic health / body condition score eye pressure
Overweight and obese dogs exhibit significantly higher intraocular pressure, with pressure rising alongside body condition score, suggesting obesity-related metabolic and mechanical changes may increase glaucoma risk and represent a modifiable factor for canine ocular health.
Iterative Health Adds Nadege Gunn as CMO, Hepatology and Obesity
February 12, 2026 / hepatology clinical research / metabolic liver disease / obesity clinical trials / MASLD MASH therapeutics / biopharma research networks
Iterative Health appointed hepatologist Nadege Gunn, MD, as CMO to lead strategic clinical research in metabolic liver disease and obesity, expanding multispecialty trial networks and accelerating development of novel hepatology and obesity therapies.
Vida Health Expands Cardiometabolic Care to Include MASH, Addressing a Fast-Growing Obesity-Related Cost Driver
February 10, 2026 / MASH treatment obesity / metabolic liver disease care / GLP-1 therapy management / virtual cardiometabolic health / obesity-related liver disease
Vida Health expanded its virtual obesity platform to include noncirrhotic MASH care, integrating lifestyle intervention, behavioral health, and selective GLP-1 use to address obesity-driven liver disease while supporting cost-effective, longitudinal cardiometabolic management.
Tirzepatide shows dual benefits in sleep apnea trial improving metabolism and reducing inflammation
February 9, 2026 / tirzepatide obstructive sleep apnea / SURMOUNT-OSA trial / GLP-1 GIP dual agonist / cardiometabolic inflammation / obesity sleep-disordered breathing
In the SURMOUNT-OSA Phase 3 trials, tirzepatide improved obstructive sleep apnea severity, blood pressure, insulin resistance, and inflammatory markers in adults with obesity, suggesting combined metabolic and respiratory benefits beyond weight loss alone.
High-fat diets cause more damage to metabolic health than carbohydrates
February 10, 2026 / high-fat diet metabolic risk / ketogenic diet liver damage / insulin resistance inflammation / saturated fat health effects / metabolic liver disease research
In a mouse study, high-fat and ketogenic diets caused greater weight gain, insulin resistance, inflammation, and liver fat accumulation than high-carbohydrate diets, suggesting saturated fat excess may drive more severe metabolic and hepatic dysfunction.
Obesity drives one in ten infectious disease deaths
February 9, 2026 / obesity infectious disease risk / BMI infection mortality / severe infection hospitalization / obesity immune dysfunction / global health obesity burden
Large cohort data show obesity increases severe infectious disease risk by 70%, with higher BMI linked to greater hospitalization and mortality across bacterial and viral infections, positioning obesity as a significant contributor to global infection-related deaths.
Gut microbiome insights shed light on rising youth-onset type 2 diabetes
February 13, 2026 / youth-onset type 2 diabetes / gut microbiome obesity / bacterial biomass inflammation / pediatric metabolic risk / microbiome-based prevention
Emerging data link reduced gut bacterial biomass to inflammation and metabolic dysfunction in youth obesity, highlighting microbiome-informed risk assessment—particularly sex-specific effects—as a potential strategy to prevent youth-onset type 2 diabetes.
Review links betel nut addiction to cancer, heart disease, and metabolic risks
February 11, 2026 / betel nut addiction / arecoline neurobiology / oral cancer risk / metabolic syndrome association / cardiovascular disease inflammation
Betel nut addiction, driven by arecoline-mediated cholinergic and dopaminergic effects, is linked to oral cancer, cardiovascular disease, insulin resistance, and metabolic syndrome, underscoring significant global public health risks and limited evidence-based treatment options.
Even Modest Weight Loss Linked to Improvement in Liver Fibrosis
February 16, 2026 / MASLD MASH weight loss / liver fibrosis improvement / metabolic liver disease treatment / lifestyle intervention MASH / GLP-1 liver outcomes
Meta-analysis shows modest weight loss (>3%) in MASLD/MASH is associated with higher rates of MASH resolution and fibrosis improvement, supporting lifestyle-driven weight reduction as a clinically meaningful strategy to slow liver disease progression.
In proof-of-concept trial, daily pill lowers blood, liver fat levels in MASLD
February 16, 2026 / MASLD oral therapy / TLC-2716 LXR modulator / triglyceride reduction trial / metabolic liver disease treatment / cardiometabolic risk management
In a Phase 2a trial, the oral LXR modulator TLC-2716 significantly reduced fasting triglycerides and liver fat in overweight adults with MASLD, supporting its potential as a gut–liver–targeted therapy for metabolic liver and cardiometabolic disease.
Coalition to push for earlier diagnosis of fatty liver disease MASLD
February 9, 2025 / MASLD early diagnosis / noninvasive liver fibrosis testing / MASH detection tools / fatty liver disease screening / metabolic liver disease prevention
A new MASLD Diagnostic Coalition aims to expand access to noninvasive fibrosis testing, promoting earlier detection of fatty liver disease to prevent progression to MASH, cirrhosis, and hepatocellular carcinoma amid rising cardiometabolic risk.
Genetic link between type 2 diabetes and high blood pressure uncovered
February 10, 2026 / type 2 diabetes hypertension genetics / polygenic risk scores / cardiometabolic comorbidity / precision medicine prevention / metabolic syndrome pathways
Large-scale genetic analysis identified shared but mechanistically distinct pathways linking type 2 diabetes and hypertension, with partitioned polygenic scores improving prediction of cardiometabolic comorbidity and supporting precision prevention and personalized risk stratification.
Type 2 diabetes and hypertension share a genetic link, study shows
February 10, 2026 / type 2 diabetes hypertension link / shared genetic architecture / polygenic risk stratification / cardiometabolic disease prediction / precision medicine genetics
Genetic analysis of over 1,300 variants reveals shared but heterogeneous pathways linking type 2 diabetes and hypertension, with partitioned polygenic scores identifying high-risk subgroups and supporting earlier, precision-based cardiometabolic risk stratification.
Too much sitting increases risk of multiple diseases, experts warn
February 13, 2026 / sedentary lifestyle risks / prolonged sitting health effects / cardiovascular disease risk / metabolic syndrome obesity / physical inactivity mortality
Prolonged sedentary behavior is associated with increased risks of cardiovascular disease, type 2 diabetes, metabolic syndrome, musculoskeletal disorders, cognitive decline, and premature mortality, with evidence suggesting uninterrupted sitting independently contributes to systemic metabolic and vascular dysfunction.
GLP-1s in Young Adults: Rethinking Metabolic Risk and Early Intervention
February 16, 2025 / GLP-1 young adults / early metabolic intervention / obesity prevention therapy / insulin resistance management / cardiometabolic risk reduction
Early GLP-1 therapy in young adults with obesity or insulin resistance may preserve beta-cell function, reduce cardiometabolic risk, and prevent progression to type 2 diabetes, emphasizing proactive intervention, careful candidate selection, and integration with lifestyle and reproductive planning.